옵션 체인은 다양한 행사가격과 만기일에 대한 Calidi Biotherapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Calidi Biotherapeutics에 대한 시장 심리를 평가합니다..

Calidi Biotherapeutics (AMEX:CLDI) 주식, 옵션 체인

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

News

COLL

COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced it will transfer its stock listing <a href="https://www.benzinga.com/pressreleases/24/11/b41988795/palantir-announces-transfer-of-stock-exchange-listing-to-nasdaq">to the Nasdaq</a>.
What Happened: After the market close on Thursday, Palantir announced that it would transfer the listing of its Class A common stock from the New York Stock Exchange to the Nasdaq Global Select Market.
Palantir said it expects to begin trading as a Nasdaq-listed company on Nov. 26. The stock will continue to trade under the ticker symbol &#8220;PLTR.&#8221;
&#8220;Upon transferring, Palantir anticipates meeting the eligibility requirements of the Nasdaq-100 Index,&#8221; the company said.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a>
Palantir has been one of the hottest stocks of the year, having gained approximately 245% year-to-date, driven by the company&#8217;s positioning in the <a href="http://benzinga.com/topic/ai">AI</a> space. 
Palantir shares really took off at the beginning of November after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">strong quarterly results</a> driven by&nbsp;"unrelenting" AI demand. 
Revenue jumped 30% year-over-year on continued strength in the U.S. customer count grew 39% year-over-year after the company closed 104 deals worth over $1 million during the quarter.
"The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,&#8221;&nbsp;Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders.
PLTR Price Action: Palantir shares were up 3.87% in after-hours, trading at $61.47 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

Tech

PLTR

Palantir Stock Is Rising After The Bell: What's Going On?

Trading Ideas

GOOG

GOOGL

Pershing Square Capital's Q3 2024 13F Filing Reveals Reduced Stakes In Hilton Worldwide By 18% To 7.37M Shares, Chipotle Mexican Grill By 8%, Restaurant Brands Intl By 1% To 23.0M Shares, And Alphabet Class C And Class A By 9%

Pershing Square Capital's Q3 2024 13F Filing Shows New Stakes In Brookfield Corp With 25.88M Shares, Nike With 13.24M Shares, And Seaport Entertainment Group With 2.09M Shares Each In Common Stock And Rights

Hedge Funds

General

RBLX

ValueAct Holdings' Q3 2024 13F Filing Indicates Increased Stakes In Walt Disney By 22% To 7.46M Shares And Roblox By 341% To 10.14M Shares

LLYVA

LLYVK

ValueAct Holdings' Q3 2024 13F Filing Shows New Stakes In Meta Platforms With 211.5K Shares, Live Nation Entertainment With 1.01M Shares, Visa With 373.6K Shares, Liberty Media Corp Series C With 1.34M Shares, And Liberty Media Corp Series A With 671.8K Shares

The loss is primarily attributable to a non-cash change in fair value of warrant liabilities related to common share price and warrant price appreciation during the quarter, production restart related operating expenses, and interest expense.

Earnings

Sable Offshore Reports Q3 Net Income Of $(255.6)M

Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. The company reported quarterly sales of $1.926 million which beat the analyst consensus estimate of $1.000 million by 92.60 percent. This is a 647.65 percent increase over sales of $257.606 thousand the same period last year.

Earnings Beats

MRKR

Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate

Telsey Advisory Group analyst Dana Telsey maintains Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) with a Market Perform and maintains $2 price target.

Price Target

Analyst Ratings

LVLU

Telsey Advisory Group Maintains Market Perform on Lulus Fashion Lounge, Maintains $2 Price Target

XWEL

XWELL Q3 Revenue $8.4M Up From $7.5M YoY

NNOX

NVDA

RXRX

Nvidia 13F Shows Decreased Stake In Arm Holdings By 13% From 320,823 To 280,411 Shares; Decreased Stake In Recursion Pharmaceuticals By 12% From 57,797 To 50,784 Shares; Decreased Stake In Nano X Imaging Ltd By 17% From 437 To 362 Shares

Earnings Misses

POET

POET Technologies Q3 2024 GAAP EPS $(0.20) Misses $(0.090) Estimate

Contracts

Eaton Says It Has Been Selected By MDA Space To Deliver High-performance Propellant Storage Tanks

SERV

SOUN

Nvidia 13F Shows Increased Stake In Serve Robotics Inc By 308% From 7,267 To 29,629 Shares; Increased Stake In SoundHound AI By 18% From 6,836 To 8,065 Shares

WIIM

OKLO

Oklo shares are trading lower. The company reported Q3 financial results.

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform and raises the price target from $183 to $190.

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Raises Price Target to $190

ASML

MSCI

Third Point 13F Shows Exited Position In International Flavors & Fragrances, Previously Holding 1,300,000 Shares; Advance Auto Parts, Previously Holding 1,500,100 Shares; ASML Holding, Previously Holding 80,000 Shares; MSCI, Previously Holding 150,000 Shares; Micron Technology Inc, Previously Holding 275,000 Shares

Retractable Technologies Q3 Sales $10.3M, Flat YoY

Federal Reserve Chair Jerome Powell's unexpectedly hawkish remarks on Thursday sent markets into a tailspin. Major U.S. equity indices closed in the red, and the dollar soared for <a href="https://www.benzinga.com/topic/interest-rates">a fifth consecutive session</a>.
In a speech to Dallas business leaders, Powell highlighted the remarkable strength of the U.S. economy, indicating that there's no need for the Fed to &#8220;be in a hurry to lower rates.&#8221;
He reiterated the central bank's commitment to reaching its 2% inflation target, stressing the need for careful decision-making as inflation remains above desired levels.
He highlighted productivity gains, which he said have &#8220;grown faster over the past five years than at any point in the two decades preceding the pandemic,&#8221; positioning the U.S. economy as &#8220;the best-performing among major economies.&#8221;
Addressing the October <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">producer price index (PPI) uptick</a>, Powell labeled it &#8220;more than an upward bump&#8221; but maintained confidence in the trajectory toward the 2% inflation goal.
<h3 class="wp-block-heading">Markets Reassess Interest Rate Path: Traders Are Less Confident On A December Cut</h3>
Powell&#8217;s comments impacted the interest-rate market, with fed futures now reflecting a reduced likelihood of a 25-basis-point cut in December. 
The CME FedWatch tool shows the odds of such a move dropped to 58%, sharply down from around 80% earlier in the day.
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed down 0.6%, fully erasing gains from last week&#8217;s rate cut. Energy was the only sector in positive territory, rising 0.4%, while industrials and health care led declines, each down 0.7%.
Top performers in the S&amp;P 500 included Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), and First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), which rose 12.8%, 8.7%, and 7.2%, respectively. Among the laggards were Leidos Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) and Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), down 13.6% and 11.4%, respectively.
Tech stocks, as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), declined 0.7%, marking a fourth consecutive loss. Blue chips followed by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) slipped 0.5%, while small caps in the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) underperformed, falling 1.3%.
The dollar continued to attract liquidity, with the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) logging a fifth consecutive gain, reaching levels last seen in late October 2023.
Treasury yields also rose, with the 10-year yield closing at 4.46%. Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), marked its fifth straight loss.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was 1.7% lower in the past 24 hours to $88,013 at 5:21 p.m. ET, on track for its worst day in November.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984852/trumps-red-wave-pushes-emerging-market-stocks-to-2-month-lows-volatility-expected-to-remain-elevated">Trump&#8217;s Red Wave Pushes Emerging Market Stocks To 2-Month Lows: Volatility &#8216;Expected To Remain Elevated&#8217; </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Bonds

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Currency ETFs

Treasuries

Economics

Federal Reserve

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

FSLR

LDOS

SMCI

PowerShares DB US Dollar Index Bullish Fund

WYNN

Powell's Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips

TMC Metals shares are trading higher. The company reported Q3 financial results.

Calidi Biotherapeutics warrants delist from NYSE

Calidi (CLDI) Biotherapeutics will present data supporting RTNova, the company's systemic antitumor virotherapy platform, at the International Onco...

Calidi to present data supporting RTNova at upcoming conferences

Warning: CLDI is at high risk of performing badly

Calidi Biotherapeutics GAAP EPS of -$0.65

Calidi Biotherapeutics announces proposed offering

Calidi (CLDI) Biotherapeutics announced that it intends to offer to sell shares of its common stock in an public offering. All of the shares of com...

Calidi announces common stock offering, no amount given

Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock

Calidi (CLDI) Biotherapeutics has priced its public offering of 4,437,869 shares of the Company's common stock at a price of $1.69 per share. The c...

Calidi prices 4.4M shares at $1.69 in public offering

CLDI

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

CADL

CGON

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Press Releases

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Financing

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Proposed Public Offering

IPOs

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

BOXL

GRRR

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Clene

CEL-SCI

Elevation Oncology

Fortress Biotech

FibroGen

HOOKIPA Pharma

Immix Biopharma

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kala Bio

Lantern Pharma

Lumos Pharma

NextCure

OKYO Pharma

Passage Bio

Pluri

Rallybio

Serina Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

X4 Pharmaceuticals

Xilio Therapeutics

Ladenburg Thalmann

Baird

HC Wainwright & Co.

Calidi Biotherapeutics shares are trading lower after the company announced the pricing of its $7.5 million public offering of 4,437,869 shares at a price of $1.69 per share.

Comments

Calidi Biotherapeutics

Calidi Biotherapeutics (CLDI) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌